Latest news
Swedish kiss for french Innate: Sobi backs Innate’s lacutamab as rare T-cell lymphoma program enters Phase 3 - European Biotechnology MagazineEuropean Biotechnology Magazine · Mon, 10 Aug 2026 14:03:25 GMTM&A Roundup: Novo Nordisk Enters AI Drug Discovery Partnership with Amazon, Innate Pharma Partners with Sobi, Innovent Enters Commercialization Agreement with Daiichi Sankyo - Pharmaceutical ExecutivePharmaceutical Executive · Mon, 10 Aug 2026 13:53:58 GMTInnate Pharma S.A. and Swedish Orphan Biovitrum AB Enter Licensing Agreement for Lacutamab in T-Cell Lymphoma - marketscreener.commarketscreener.com · Mon, 10 Aug 2026 11:52:53 GMTSobi licenses Innate’s CTCL drug for up to $580m as it heads to Phase III - Pharmaceutical TechnologyPharmaceutical Technology · Mon, 10 Aug 2026 11:21:59 GMTSobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 push - Fierce BiotechFierce Biotech · Mon, 10 Aug 2026 11:13:48 GMTNews round-up Monday, August 10 - BiostockBiostock · Mon, 10 Aug 2026 10:29:39 GMTInnate Pharma (NASDAQ: IPHA) secures Sobi deal, $75M upfront and Phase 3 push - stocktitan.netstocktitan.net · Mon, 10 Aug 2026 10:05:10 GMTSobi partners with Innate Pharma in $580m lacutamab deal to expand rare cancer portfolio - TipRanksTipRanks · Mon, 10 Aug 2026 06:42:09 GMT